{"id":56921,"date":"2024-03-20T12:00:31","date_gmt":"2024-03-20T12:00:31","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=56921"},"modified":"2024-04-01T18:51:34","modified_gmt":"2024-04-01T18:51:34","slug":"the-role-of-seasonal-influenza-in-compounding-the-outbreak-of-infectious-diseases-a-critical-review","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol17no1\/the-role-of-seasonal-influenza-in-compounding-the-outbreak-of-infectious-diseases-a-critical-review\/","title":{"rendered":"The Role of Seasonal Influenza in Compounding the Outbreak of Infectious Diseases: A Critical Review"},"content":{"rendered":"\n

Introduction<\/strong><\/p>\n\n\n\n

Infectious diseases pose a\nsignificant threat to global public health, and various factors often\nexacerbate their impact. One such influential factor is the seasonal influenza\nvirus, which not only presents a substantial health challenge but also plays a\npivotal role in compounding the outbreak and spread of other infectious\ndiseases1<\/sup>. Seasonal influenza, commonly known as the flu, is a\nhighly contagious respiratory infection caused by influenza viruses which typically manifests with\nsymptoms such as fever, cough, sore throat, and muscle aches2<\/sup>. While\nthe influenza virus is a significant health concern in itself, its role in\nexacerbating the impact of other infectious diseases cannot be understated as\nthe seasonal nature of influenza creates a recurrent challenge for healthcare\nsystems worldwide 3<\/sup>. The virus tends to peak during specific\nperiods, placing additional strain on healthcare resources and personnel. As\nthese resources are diverted to manage influenza cases, the capacity to\neffectively respond to other infectious diseases diminishes, creating an\nenvironment conducive to the rapid spread of additional pathogens4<\/sup>.Furthermore, the immunomodulatory effects of influenza can compromise\nindividuals’ immune responses, rendering them more susceptible to secondary\ninfections. The influenza virus weakens the immune system by interfering with\nthe body’s ability to mount an effective defence against pathogens5,6<\/sup>.\nThis immune suppression not only prolongs the recovery from influenza itself\nbut also heightens the risk of acquiring and spreading other infectious\ndiseases. For instance, individuals infected with influenza may experience\ndamage to the respiratory epithelium, creating an entry point for opportunistic\npathogens7,8<\/sup>. Bacterial co-infections, such as pneumonia, are common\ncomplications of influenza and significantly contribute to the severity of\nillness and mortality rates9<\/sup>. <\/p>\n\n\n\n

The interplay between influenza and\nsecondary infections underscores the importance of comprehensive vaccination\nstrategies and prompt medical interventions to mitigate the compounding effects\non public health10,11<\/sup>. Moreover, the similarities in symptoms\nbetween influenza and various other respiratory infections can pose challenges\nin timely and accurate diagnosis. Amid an influenza outbreak, distinguishing\nbetween influenza and emerging infectious diseases becomes a formidable task\nfor healthcare professionals. This diagnostic challenge delays appropriate\ntreatment and containment measures, allowing the co-occurrence of multiple\ninfectious diseases to escalate within communities. Addressing the compounding\nrole of seasonal influenza in infectious disease outbreaks requires integrated\npublic health strategies. Comprehensive influenza vaccination campaigns,\nstrengthened surveillance systems, and robust healthcare infrastructure are\nessential components of a proactive approach12<\/sup>. Timely and accurate\ndiagnosis, coupled with effective treatment protocols, can minimize the impact\nof influenza on individuals and prevent the synergistic effects of other\ninfectious diseases. Therefore, this review provides an insight into the\nvarious ways in which seasonal influenza contributes to the complexity of\ninfectious disease outbreaks.<\/p>\n\n\n\n

Healthcare system overload<\/strong><\/p>\n\n\n\n

Infectious disease outbreaks pose\nsignificant challenges to healthcare systems worldwide with a sudden surge in\ncases, the need for rapid response, and the strain on resources can lead to\nhealthcare system overload13<\/sup>. One of the primary mechanisms through\nwhich seasonal influenza compounds infectious disease outbreaks is by straining\nhealthcare systems.10<\/sup> The cyclical nature of influenza creates\nannual spikes in cases, leading to a surge in hospital admissions and\noutpatient visits14,15<\/sup>. The increased demand for medical resources,\npersonnel, and treatment facilities during flu seasons diverts attention and\nresources away from addressing other emerging infectious diseases. As\nhealthcare providers grapple with the influx of influenza cases, their ability\nto effectively respond to concurrent outbreaks diminishes, creating a domino\neffect that hampers overall public health response capabilities16,17<\/sup>. Infectious disease outbreaks,\nparticularly those with high transmission rates, can deplete essential medical\nresources18,19<\/sup>. Personal protective equipment (PPE), ventilators,\nmedications, and diagnostic tools become scarce, affecting the quality of care\nprovided to patients20<\/sup>. Healthcare personnel face increased\nworkloads, long hours, and heightened stress, potentially compromising their\nability to deliver optimal care. Staff shortages, whether due to illness or\nburnout, exacerbate the strain on the healthcare workforce. Outbreaks can present logistical\nchallenges in managing patient flow and maintaining infection control measures21<\/sup>.\nDesignated isolation areas, intensive care units, and other critical spaces may\nbecome overwhelmed, hindering the ability to segregate infected individuals\nfrom the general population22<\/sup>. Limited space and facilities\ncontribute to the difficulties in implementing effective triage, isolation, and\ntreatment strategies23<\/sup>.<\/p>\n\n\n\n

During infectious disease outbreaks,\nthe focus on treating infected individuals can lead to delays in providing care\nfor non-infectious conditions such as routine medical procedures, elective\nsurgeries, and treatments for chronic illnesses that may be postponed or\ncancelled24,25<\/sup>. Patients with conditions unrelated to the outbreak\nmay face challenges accessing timely and appropriate healthcare services,\npotentially leading to adverse health outcomes26<\/sup>. Effective communication is paramount\nduring infectious disease outbreaks, both within the healthcare system and with\nthe public. Overload can strain communication channels, leading to delays in\ndisseminating critical information to healthcare providers, patients, and the\nbroader community27<\/sup>. Misinformation and a lack of clear\ncommunication can contribute to panic, fear, and a breakdown in public trust28<\/sup>. Miscommunication can lead to panic,\nmisinformation, and a loss of public trust, further complicating the healthcare\nsystem’s ability to manage the outbreak effectively. Recurring infectious\ndisease outbreaks can erode the overall resilience of healthcare systems and if\nthe systems are consistently stretched to their limits without sufficient\nrecovery periods, they become more vulnerable to subsequent crises29<\/sup>.\nLong-term strain can result in a diminished capacity to handle future\noutbreaks, exacerbating the potential for healthcare system overload during\ninfectious disease outbreaks with wide-ranging implications30<\/sup>. <\/p>\n\n\n\n

Healthcare personnel face\nunprecedented challenges during infectious disease outbreaks because their\nincreased workload, prolonged working hours, and exposure to high-stress\nsituations contribute to burnout among healthcare professionals31,32<\/sup>.\nStaff shortages, whether due to illness among healthcare workers or an\noverwhelmed workforce, further compound the strain on the healthcare system33<\/sup>.\nThe mental health and well-being of healthcare workers become critical considerations\nin maintaining a functional healthcare response amid an infectious disease\noutbreak, routine healthcare services are often disrupted34<\/sup>.\nElective surgeries, preventive screenings, and management of chronic illnesses\nmay be postponed or cancelled to redirect resources and personnel toward\naddressing the outbreak leading to delayed diagnoses, progression of chronic\nconditions, and long-term health consequences for individuals not directly\naffected by the infectious disease35,36<\/sup>. The disruption of healthcare\nsystems during infectious disease outbreaks is a multifaceted challenge that\nrequires careful planning, resource allocation, and effective communication.\nBuilding resilient healthcare systems that can adapt to surges in demand,\nensuring a robust supply chain for medical resources, and prioritizing the\nwell-being of healthcare workers are crucial components of mitigating the\ndisruption caused by infectious disease outbreaks. A comprehensive and\ncoordinated approach is essential to minimize the impact on patient care and\nprotect public health during these challenging times.<\/p>\n\n\n\n

Immune compromise and co-infections<\/strong><\/p>\n\n\n\n

In the context of infectious disease\noutbreaks, the compromised immune status of individuals can significantly\nimpact the course and severity of infections37<\/sup>. Immune compromise\nmay result from various factors, including the primary infectious agent,\ncoexisting health conditions, or treatments received.38<\/sup> Seasonal\ninfluenza can compromise the immune system, making individuals more susceptible\nto secondary infections because the virus weakens the respiratory epithelium,\ncreating an opportune environment for other pathogens to invade39<\/sup>.\nBacterial co-infections, particularly pneumonia, frequently accompany influenza\ncases, contributing to increased morbidity and mortality rates40<\/sup>.\nThis synergy between influenza and secondary infections underscores the\nimportance of addressing not only the primary infection but also its potential\ncascading effects on overall health. Seasonal influenza has immunomodulatory effects\nthat can compromise the immune response of individuals as the virus weakens the\nrespiratory epithelium, creating a favourable environment for opportunistic\ninfections41,42<\/sup>. Individuals infected with influenza become more\nsusceptible to secondary bacterial infections, such as pneumonia which\nincreased the susceptibility not only prolongs the recovery from influenza but\nalso escalates the severity of other infectious diseases that may co-occur,\nleading to a compounding effect on overall public health42,43<\/sup>.\nInfectious diseases, particularly those affecting the respiratory system, can\ncompromise the integrity of the respiratory epithelium which serves as an entry\npoint for opportunistic pathogens, leading to co-infections44<\/sup>. In\nthe context of outbreaks like influenza or COVID-19, the initial viral\ninfection may damage the respiratory epithelium, facilitating secondary\nbacterial infections such as pneumonia while co-infections often result in more\nsevere clinical outcomes and increased mortality rates45<\/sup>. Individuals with pre-existing health\nconditions, such as diabetes, cardiovascular disease, or immunodeficiency\ndisorders, are often more susceptible to infectious diseases and also the\npresence of chronic illnesses can compromise the immune system’s ability to\nmount an effective defence against pathogens46<\/sup>. During outbreaks,\nindividuals with underlying health conditions may experience more severe forms\nof the primary infection and are at an increased risk of acquiring\nco-infections47<\/sup>.<\/p>\n\n\n\n

Similarly, medical interventions\nused to treat infectious diseases, such as immunosuppressive drugs or certain\nantiviral therapies, can induce immune suppression48<\/sup>. While these\ntreatments are essential for managing the primary infection, they may\ninadvertently increase the risk of co-infections. Striking a balance between\ncontrolling the outbreak and minimizing treatment-induced immune compromise is\na delicate challenge in infectious disease management. Co-infections in the context of immune compromise often result in\nmore severe clinical outcomes that can lead to a synergistic effect, causing a\nmore profound and prolonged illness49,50<\/sup>. This poses challenges for\nhealthcare providers in terms of treatment strategies, as managing\nco-infections requires a comprehensive and tailored approach to address the\nunique aspects of each pathogen. Vaccination campaigns targeting both the primary infectious agent\nand common secondary pathogens can mitigate the risk of co-infections. However,\npublic health strategies should consider the vulnerability of specific\npopulations, such as individuals with chronic illnesses or those undergoing\nimmune-suppressive treatments, to tailor interventions and preventive measures\naccordingly25<\/sup>. Infectious disease outbreaks create a complex landscape where\nimmune compromise significantly influences the dynamics of co-infections.\nRecognizing the interplay between the primary infectious agent, compromised\nimmune responses, and secondary pathogens is essential for designing effective\ncontrol strategies. By addressing immune compromise in the context of\noutbreaks, public health efforts can better protect vulnerable populations and\nmitigate the impact of co-infections on overall morbidity and mortality51,52<\/sup>.<\/p>\n\n\n\n

Diagnostic challenges and delayed\nintervention <\/strong><\/p>\n\n\n\n

In the context of infectious disease\noutbreaks, timely and accurate diagnosis is critical for effective control and\nmanagement. However, the complex nature of outbreaks often introduces\ndiagnostic challenges, leading to delayed intervention as shown in Table 1. The\noverlap in symptoms between influenza and various other infectious diseases\npresents a challenge in timely and accurate diagnosis53<\/sup>. During an\ninfluenza outbreak, the similarity in clinical presentations hampers the\nability to differentiate between influenza and emerging pathogens54<\/sup>.\nThe lack of prompt and precise diagnostic tools may result in delayed\ninterventions and the inadvertent facilitation of the concurrent spread of\nmultiple infectious agents within communities. Timely diagnosis is crucial for\neffective containment measures, and the failure to promptly identify and\nisolate cases contributes to the compounding effect of infectious diseases. One\nof the primary reasons for diagnostic challenges in infectious disease\noutbreaks is the similarity in clinical presentations among different pathogens55<\/sup>.\nMany infectious diseases share common symptoms, such as fever, cough, and\nfatigue, making it difficult to differentiate between them based solely on\nclinical observation55,56<\/sup>. This lack of specificity hampers healthcare\nprofessionals’ ability to quickly and accurately identify the causative agent,\ndelaying appropriate intervention. During the early stages of an outbreak, access to rapid and\nreliable diagnostic tools may be limited. <\/p>\n\n\n\n

Table 1: An outline of the diagnostic challenges and potential delays in intervention during disease outbreaks<\/strong>.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Diagnostic Challenge<\/strong><\/p>\n<\/td>\n

\n

Description<\/strong><\/p>\n<\/td>\n

\n

Delayed Intervention Consequences<\/strong><\/p>\n<\/td>\n

\n

References<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n

\n

Asymptomatic Cases<\/strong><\/p>\n<\/td>\n

\n

Difficulty in identifying individuals who are carriers of the disease but show no symptoms.<\/p>\n<\/td>\n

\n

Spread of the disease within communities as asymptomatic carriers unknowingly transmit the infection.<\/p>\n<\/td>\n

\n

57<\/p>\n<\/td>\n<\/tr>\n

\n

Limited Access to Testing<\/strong><\/p>\n<\/td>\n

\n

Insufficient availability of diagnostic tests, leading to delays in confirming cases.<\/p>\n<\/td>\n

\n

Delayed identification of infected individuals, hindering timely isolation, contact tracing, and treatment.<\/p>\n<\/td>\n

\n

58<\/p>\n<\/td>\n<\/tr>\n

\n

Symptom Similarity<\/strong><\/p>\n<\/td>\n

\n

Similar symptoms with other common illnesses may lead to misdiagnosis or delayed recognition.<\/p>\n<\/td>\n

\n

Delayed initiation of appropriate treatment and increased risk of secondary transmission due to undetected cases.<\/p>\n<\/td>\n

\n

59<\/p>\n<\/td>\n<\/tr>\n

\n

Variable Incubation Periods<\/strong><\/p>\n<\/td>\n

\n

Different individuals may exhibit varying incubation periods, making it challenging to predict onset.<\/p>\n<\/td>\n

\n

Difficulties in determining the optimal timing for intervention measures such as quarantine and contact tracing.<\/p>\n<\/td>\n

\n

 <\/p>\n

        60<\/p>\n<\/td>\n<\/tr>\n

\n

Limited Healthcare Infrastructure<\/strong><\/p>\n<\/td>\n

\n

Inadequate resources and healthcare facilities may hinder rapid diagnostic processes.<\/p>\n<\/td>\n

\n

Overwhelmed healthcare systems, increased patient load, and reduced capacity to respond effectively to the outbreak.<\/p>\n<\/td>\n

\n

61<\/p>\n<\/td>\n<\/tr>\n

\n

Inadequate Surveillance Systems<\/strong><\/p>\n<\/td>\n

\n

Lack of robust monitoring systems may result in delayed detection of unusual patterns.<\/p>\n<\/td>\n

\n

Delayed recognition of outbreaks, hinders the ability to implement timely public health measures and control the spread of the disease.<\/p>\n<\/td>\n

\n

62<\/p>\n<\/td>\n<\/tr>\n

\n

Globalization and Travel<\/strong><\/p>\n<\/td>\n

\n

Increased international travel may lead to delayed identification of cases in different regions.<\/p>\n<\/td>\n

\n

Global spread of the disease, making containment and control efforts more challenging.<\/p>\n<\/td>\n

\n

63<\/p>\n<\/td>\n<\/tr>\n

\n

Stigma and Fear<\/strong><\/p>\n<\/td>\n

\n

Social stigma and fear associated with the disease may lead to underreporting and delayed seeking of healthcare.<\/p>\n<\/td>\n

\n

Increased risk of community transmission as individuals may avoid testing or treatment due to fear of discrimination or isolation.<\/p>\n<\/td>\n

\n

64<\/p>\n<\/td>\n<\/tr>\n

\n

Insufficient Public Awareness<\/strong><\/p>\n<\/td>\n

\n

Lack of awareness about symptoms, preventive measures, and available resources.<\/p>\n<\/td>\n

\n

Delayed reporting of symptoms, leads to delays in seeking healthcare and implementation of preventive measures.<\/p>\n<\/td>\n

\n

65<\/p>\n<\/td>\n<\/tr>\n

\n

Laboratory Capacity Issues<\/strong><\/p>\n<\/td>\n

\n

Inadequate laboratory facilities and trained personnel for timely and accurate testing.<\/p>\n<\/td>\n

\n

Delays in confirming cases hindered contact tracing and challenges in implementing appropriate control measures.<\/p>\n<\/td>\n

\n

67<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n

Developing and deploying diagnostic\ntests for a novel pathogen can take time, and in resource-constrained settings,\nthe availability of such tests may be further delayed. The absence of\npoint-of-care diagnostics contributes to delays in confirming cases, isolating\nindividuals, and implementing targeted public health measures. Infectious disease outbreaks often\noccur in regions with limited healthcare infrastructure and resources.\nLogistical challenges, including transportation of samples, establishing\ntesting centres, and ensuring a reliable supply chain for diagnostic reagents,\ncan contribute to delays in the testing process68,69<\/sup>. The lack of a\nrobust infrastructure impedes the rapid scaling-up of diagnostic capabilities\nduring an outbreak. Some diagnostic tests may have inherent limitations, including high\nfalse-negative rates, especially during the early stages of infection70<\/sup>.\nFalse-negative results can lead to an underestimation of the true extent of the\noutbreak, contributing to delayed intervention71<\/sup>. Therefore, the\nneed for confirmatory testing and retesting individuals with initial negative\nresults further complicates the diagnostic process. The effectiveness of outbreak\nresponse relies on robust surveillance and reporting systems72<\/sup>. In\nregions where surveillance infrastructure is inadequate or reporting mechanisms\nare inefficient, delays in identifying and reporting cases occur73<\/sup>.\nThis lack of real-time data compromises the ability of public health\nauthorities to implement timely and targeted interventions, allowing the\noutbreak to escalate. Public awareness and the stigma associated with infectious diseases\ncan also contribute to delayed intervention as such, individuals may be\nhesitant to seek medical attention due to fear of social isolation or\ndiscrimination74,75<\/sup>. This delay in seeking care not only impacts the\naffected individuals but also allows the infectious agent to spread further\nwithin communities before appropriate interventions can be implemented. <\/p>\n\n\n\n

In an interconnected world, delayed\nsharing of information between countries and regions can impede the global\nresponse to infectious disease outbreaks76<\/sup>. Political, logistical,\nor diplomatic challenges may hinder the timely exchange of data, hindering the\ninternational community’s ability to coordinate efforts and deploy resources\neffectively 77,78<\/sup>. Diagnostic challenges and delayed intervention in infectious\ndisease outbreaks are multifaceted issues that require a comprehensive and\ncoordinated response. Addressing these challenges necessitates investment in\nrapid and accurate diagnostic technologies, strengthening healthcare\ninfrastructure, improving surveillance systems, and promoting global\ncooperation for timely information sharing. By addressing these factors, public\nhealth authorities can enhance their capacity to identify, respond to, and\ncontrol infectious disease outbreaks in a more effective and timely manner.<\/p>\n\n\n\n

Public health strategies and\npreparedness <\/strong><\/p>\n\n\n\n

Infectious disease outbreaks pose\nsignificant threats to public health, requiring comprehensive strategies and\npreparedness measures for effective prevention, control, and response79<\/sup>.\nThe compounding effect of seasonal influenza on infectious disease outbreaks\nemphasizes the need for robust public health preparedness as outlined in Figure\n1. Comprehensive vaccination programs targeting influenza can significantly\nreduce the incidence and severity of flu cases, alleviating the burden on\nhealthcare systems 80<\/sup>. Addressing the compounding role of seasonal\ninfluenza requires a comprehensive approach to public health strategies and\npreparedness81<\/sup>. Strengthening surveillance systems and diagnostic\ncapabilities is essential for differentiating between influenza and other\ninfectious diseases promptly. Furthermore, integrated public health planning\nthat considers the seasonal patterns of influenza can enhance overall readiness\nto respond to emerging infectious diseases82<\/sup>. Timely surveillance\nand early detection are fundamental to managing infectious disease outbreaks\nbecause robust surveillance systems, incorporating real-time data collection\nand analysis, enable public health authorities to identify and monitor emerging\nthreats swiftly83<\/sup>. This includes monitoring unusual patterns of\nillness, conducting sentinel surveillance, and utilizing advanced technologies\nfor rapid detection of pathogens84<\/sup>. Early detection facilitates\nprompt intervention, containment, and the prevention of further transmission. In an interconnected world, global\ncollaboration and establishing international networks and partnerships allow\nfor the exchange of data, resources, and expertise. Organizations such as the\nWorld Health Organization (WHO) play a central role in coordinating global\nresponses, facilitating research, and providing guidance to nations facing\ninfectious disease threats. Transparent and effective communication with the public is critical\nduring infectious disease outbreaks. Public health authorities must provide\naccurate information about the nature of the outbreak, preventive measures, and\nthe current state of affairs. Engaging with communities fosters trust,\nencourages compliance with public health recommendations, and dispels\nmisinformation. Effective risk communication helps mitigate fear and panic,\npromoting a collective and informed response 85<\/sup>.<\/p>\n\n\n\n\n\n
\"\"<\/td>\n\n

Figure 1:<\/strong> Conceptualize representation of the relationships and connections between different public health strategies and preparedness measures.<\/strong><\/p>\n

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

Vaccination is a cornerstone of infectious\ndisease prevention and control. Public health strategies should include\ncomprehensive vaccination campaigns, targeting both routine immunizations and\nspecific vaccines for emerging threats. Ensuring high vaccine coverage in\npopulations helps establish herd immunity, reducing the overall transmission of\ninfectious agents and protecting vulnerable individuals86<\/sup>. Building and maintaining the\ncapacity of healthcare systems to handle infectious disease outbreaks is\ncrucial and includes training healthcare professionals, ensuring an adequate\nsupply of medical resources, and establishing surge capacity for increased\npatient numbers87<\/sup>. Resource allocation should be flexible, allowing\nfor rapid mobilization of personnel, equipment, and facilities to areas experiencing\noutbreaks. Implementation\nof quarantine and isolation measures is essential for controlling the spread of\ninfectious diseases which helps in identifying and isolating individuals with\nconfirmed or suspected infections, along with contact tracing, helps break the\nchain of transmission88<\/sup>. Public health authorities must have clear\nguidelines for implementing these measures while minimizing the social and\neconomic impact on affected individuals and communities. Investment in research\nand development for therapeutics and diagnostics is pivotal for enhancing\npreparedness. The availability of effective treatments and diagnostic tools\nexpedites patient care, facilitates early identification of cases, and informs\npublic health responses89<\/sup>. Collaboration between public and private\nsectors, as well as academia, will accelerate the development of innovative\nsolutions. Emergency preparedness plans should be in place, outlining clear\nroles and responsibilities at local, regional, and national levels as well as\nconducting regular drills and exercises to ensure that the response mechanisms\nare well-practiced and can be efficiently implemented when needed. Effective\npublic health strategies and preparedness are indispensable for managing\ninfectious disease outbreaks90<\/sup>. Communities and nations can enhance\ntheir resilience and ability to respond swiftly to emerging infectious threats\nby implementing robust surveillance, fostering global collaboration,\ncommunicating transparently with the public, and investing in research and\ndevelopment. <\/p>\n\n\n\n

Seasonal influenza and covid-19\noutbreak<\/strong><\/p>\n\n\n\n

The COVID-19 pandemic has brought\nunprecedented challenges to global public health, and understanding the\ncompounding effects of seasonal influenza on the COVID-19 outbreak is crucial10<\/sup>.\nSeasonal influenza, a recurring respiratory infection, adds complexity to the\ndynamics of the unending pandemic. Studies have shown that seasonal influenza\nserves as a compounding factor in the COVID-19 outbreak, impacting various\naspects of public health response and individual well-being 91<\/sup>. One of the most significant ways\nseasonal influenzas compound the COVID-19 outbreak is by placing an additional\nburden on healthcare systems. Both infections share similar symptoms, leading\nto an increase in hospital admissions and diagnostic challenges. The\nco-occurrence of influenza and COVID-19 cases strains medical facilities,\nexacerbating shortages in resources such as hospital beds, ventilators, and\nmedical personnel. This strain compromises the ability of healthcare systems to\neffectively manage and respond to the surge in respiratory infections92<\/sup>. Seasonal influenza and COVID-19\ndisproportionately affect similar high-risk groups, including the elderly and\nindividuals with underlying health conditions. The coexistence of these\ninfections places these vulnerable populations at an elevated risk of severe\nillness and complications. The shared susceptibility among high-risk groups\nunderscores the importance of targeted public health interventions, such as\nvaccination campaigns, to mitigate the impact of both influenza and COVID-19. <\/p>\n\n\n\n

The overlapping symptoms of seasonal\ninfluenza and COVID-19 create diagnostic challenges, leading to delays in\nidentifying and isolating cases thereby stretching testing infrastructure and\nresources when faced with the dual challenge of diagnosing both respiratory\ninfections93<\/sup>. This diagnostic complexity hampers timely\ninterventions, allowing the viruses to spread within communities. Swift and\naccurate identification of cases is critical for implementing effective\ncontainment measures and preventing further transmission of both influenza and\nCOVID-19. The\npresence of seasonal influenza alongside the COVID-19 outbreak can complicate\nindividual and public perceptions of illness94<\/sup>. Distinguishing\nbetween the two infections based solely on symptoms is challenging, leading to\nincreased anxiety and uncertainty. This confusion may contribute to the\nhesitancy in seeking medical attention, delayed testing, and adherence to\npublic health guidelines. Vaccination campaigns become even more crucial during\nthe co-occurrence of seasonal influenza and the COVID-19 outbreak95<\/sup>.\nVaccinating against influenza helps reduce the overall burden on healthcare\nsystems, minimizes the severity of flu cases, and prevents potential\nco-infections with COVID-1996<\/sup>. Coordinated efforts to promote\ninfluenza vaccination alongside COVID-19 vaccination will contribute to\nenhancing community resilience and reducing the strain on healthcare resources.<\/p>\n\n\n\n

Expert opinion on mitigating the\neffect of seasonal influenza on disease outbreak<\/strong><\/p>\n\n\n\n

Seasonal influenza poses a\nsignificant public health challenge, contributing to the burden of infectious\ndiseases worldwide. A comprehensive approach is essential to mitigate its\nimpact on public health and prevent the escalation of larger outbreaks. One of\nthe most effective ways to mitigate the impact of seasonal influenza is through\nwidespread vaccination campaigns. Annual vaccination, especially targeting\nvulnerable populations, serves as a crucial preventive measure. Governments and\nhealthcare organizations must invest in public awareness campaigns to educate\nindividuals about the benefits of vaccination. By increasing vaccine coverage,\nthe overall burden of influenza cases can be reduced, preventing the virus from\nspreading rapidly within communities. Implementing robust public health measures is vital for controlling\nthe spread of influenza and minimizing its impact on infectious disease\noutbreaks. Surveillance and monitoring systems should be strengthened to detect\ninfluenza outbreaks early. Isolation and quarantine measures can help contain\nthe virus, while social distancing strategies can reduce person-to-person\ntransmission. Promoting hygiene practices, such as regular handwashing and\nrespiratory etiquette, is essential to prevent the spread of influenza in\nvarious settings.<\/p>\n\n\n\n

Enhancing the preparedness of\nhealthcare systems is critical to handle the seasonal influx of influenza cases\neffectively. This involves increasing healthcare facility capacity, ensuring a\nsufficient supply of antiviral medications, and improving communication\nchannels between healthcare providers and public health agencies. Timely and\naccurate information dissemination is crucial for managing resources\nefficiently and providing appropriate care to individuals affected by\ninfluenza. Educating\nthe public about influenza prevention is a cornerstone in the fight against its\nspread. Public awareness campaigns should convey the importance of vaccination,\npersonal hygiene practices, and early symptom recognition. Workplace education\nprograms can play a role in preventing the spread of influenza in professional\nsettings. By fostering a culture of awareness, individuals are better equipped\nto protect themselves and their communities. In the interconnected world of today, international collaboration\nis indispensable for mitigating the effects of seasonal influenza. Countries\nshould work together to share information on influenza trends, coordinate\nresponse efforts, and collectively address challenges associated with the\nvirus. Collaborative research initiatives can lead to the development of more\neffective vaccines and treatments, benefiting global public health.<\/p>\n\n\n\n

Investment in research and\ndevelopment is paramount for staying ahead of the influenza virus. Ongoing\nsurveillance of influenza strains, coupled with research into novel vaccines\nand antiviral medications, ensures a proactive rather than reactive approach to\nthe evolving nature of the virus. Governments, academic institutions, and pharmaceutical\ncompanies should collaborate to drive innovation in influenza prevention and\ntreatment. Engaging\ncommunities in the mitigation of seasonal influenza is essential for building\nresilience. Communities should be active participants in the development and\nimplementation of preventive measures. By fostering a sense of collective\nresponsibility, individuals are more likely to adhere to recommended practices\nand contribute to the overall success of influenza prevention strategies. Mitigating the impact of seasonal\ninfluenza on the outbreak of infectious diseases requires a multifaceted and\ncollaborative approach. By prioritizing vaccination campaigns, implementing\npublic health measures, enhancing healthcare system preparedness, promoting\neducation and awareness, fostering international collaboration, investing in\nresearch and development, and engaging communities, we can collectively work\ntowards a world where the effects of seasonal influenza are minimized,\nprotecting global public health.<\/p>\n\n\n\n

Conclusion<\/strong><\/p>\n\n\n\n

The role of seasonal influenza in compounding the outbreak of\ninfectious diseases cannot be overstated. As a highly contagious respiratory\nvirus, influenza not only poses a significant health risk on its own but also\namplifies the severity and spread of other infectious diseases, creating a\ncompounding effect on public health systems. The seasonal nature of influenza\nleads to predictable surges in cases during colder months, placing additional\nstrain on healthcare infrastructure already grappling with other infectious\noutbreaks.Effective management of seasonal influenza requires a multifaceted\napproach encompassing vaccination campaigns, public awareness initiatives, and\nrobust surveillance systems to track and respond to outbreaks swiftly.By\naddressing the role of seasonal influenza in compounding infectious disease\noutbreaks, policymakers, healthcare professionals, and communities can better\nprepare and respond to future health crises, ultimately safeguarding population\nhealth and well-being.<\/p>\n\n\n\n

Acknowledgement <\/strong><\/p>\n\n\n\n

The researchers appreciate Zarqa\nUniversity for supporting this research publication<\/p>\n\n\n\n

Conflicts of Interest <\/strong><\/p>\n\n\n\n

The authors declare no conflict of\ninterest<\/p>\n\n\n\n

 Author’s contribution <\/strong><\/p>\n\n\n\n

SAH: conceived the idea and wrote\nthe first draft; AA and FE: Source the literature relevant to the review\narticle; AOJ: critically reviewed the manuscript. All authors read and approved\nthe submission of the manuscript.<\/p>\n\n\n\n

Funding source<\/strong><\/p>\n\n\n\n

No funding <\/p>\n\n\n\n

References<\/strong><\/p>\n\n\n\n

  1. Baker RE, Mahmud AS, Miller IF,\net al. Infectious disease in an era of global change. Nature Reviews Microbiology. <\/em>2022;20(4):193-205.<\/li>
  2. Lawson A, L\u00f3pez-Candales A.\nCOVID-19 and seasonal influenza. Postgraduate\nMedicine. <\/em>2022:148-151.<\/li>
  3. Piret J, Boivin G. Viral\nInterference between Respiratory Viruses. Emerging Infectious Diseases. <\/em>2022;28(2):273-281.<\/li>
  4. Hagiwara Y, Harada K, Nealon J,\nOkumura Y, Kimura T, Chaves S. Seasonal influenza, its complications and\nrelated healthcare resource utilization among people 60 years and older: A\ndescriptive retrospective study in Japan. Plos\none. <\/em>2022;17(10):e0272795-e0272795.<\/li>
  5. Javanian M, Barary M,\nGhebrehewet S, Koppolu V, Vasigala VKR, Ebrahimpour S. A brief review of\ninfluenza virus infection. Journal of\nMedical Virology. <\/em>2021;93(8):4638-4646.<\/li>
  6. Jansen JM, Gerlach T, Elbahesh\nH, Rimmelzwaan GF, Saletti G. Influenza virus-specific CD4+ and CD8+ T\ncell-mediated immunity induced by infection and vaccination. Journal of Clinical Virology. <\/em>2019;119:44-52.<\/li>
  7. Flerlage T, Boyd DF,\nMeliopoulos V, Thomas PG, Schultz-Cherry S. Influenza virus and SARS-CoV-2:\npathogenesis and host responses in the respiratory tract. Nature Reviews Microbiology. <\/em>2021;19(7):425-441.<\/li>
  8. Mifsud E, Kuba M, Barr I.\nInnate Immune Responses to Influenza Virus Infections in the Upper Respiratory\nTract. Viruses. <\/em>2021;13(10):2090-2090.<\/li>
  9. LeMessurier K, Tiwary M, Morin\nN, Samarasinghe A. Respiratory Barrier as a Safeguard and Regulator of Defense\nAgainst Influenza A Virus and Streptococcus pneumoniae. Frontiers in Immunology. <\/em>2020;11:3-3.<\/li>
  10. Dhanasekaran V, Sullivan S,\nEdwards K, et al. Human seasonal influenza under COVID-19 and the potential\nconsequences of influenza lineage elimination. Nature Communications. <\/em>2022;13(1):1721-1721.<\/li>
  11. Chen T, Attewell N, Malik A,\nLudden D, Jin MR, Chiang M. The Problems and Possibilities of Global Asias\nPedagogy. Verge: Studies in Global Asias.\n<\/em>2023;9(1):1-42.<\/li>
  12. Hudu SA, Harmal NS, Malina O,\nSekawi Z. Influenza vaccination among Malaysian healthcare workers: a survey of\ncoverage and attitudes. The Medical\nJournal of Malaysia. <\/em>2016;71(5):231-237.<\/li>
  13. Baker R, Mahmud A, Miller I, et\nal. Infectious disease in an era of global change. Nature Reviews Microbiology. <\/em>2021;20(4):193-205.<\/li>
  14. Simonsen L, Viboud C, Taylor\nRJ, Miller MA. The epidemiology of influenza and its control.  (eds)\nInfluenza Vaccines for the Future. Birkh\u00e4user Advances in Infectious Diseases.\nSpringer, Basel. https:\/\/doi.org\/10.1007\/978-3-0346-0279-2_2<\/em>.<\/li>
  15. Matias G, Taylor R, Haguinet F,\nSchuck-Paim C, Lustig R, Shinde V. Estimates of hospitalization attributable to\ninfluenza and RSV in the US during 1997\u20132009, by age and risk status. BMC Public Health. <\/em>2017;17(1):1-14.<\/li>
  16. Weeks V. Understanding\nsessional general practitioners. Education\nfor Primary Care. <\/em>2007;18(sup1):279-282.<\/li>
  17. Umpleby H, Houghton R.\nInfection prevention and surgery in the pandemic era. Surgery . <\/em>2021;39(11):722-729.<\/li>
  18. Baker RE, Mahmud AS, Miller IF,\net al. Infectious disease in an era of global change. Nature Reviews Microbiology. 2022;20(4):193-205<\/em>.<\/li>
  19. Maity B, Banerjee S, Senapati\nA, Chattopadhyay J. Quantifying optimal resource allocation strategies for\ncontrolling epidemics. Journal of the\nRoyal Society Interface. <\/em>2023;20(202):20230036-20230036.<\/li>
  20. Sigala IF, Sirenko M, Comes T,\nKov\u00e1cs G. Mitigating personal protective equipment (PPE) supply chain\ndisruptions in pandemics-a system dynamics approach. International Journal of Operations and Production Management. <\/em>2022;42(13):128-154.<\/li>
  21. Nash R, Nouvellet P, Cori A.\nReal-time estimation of the epidemic reproduction number: Scoping review of the\napplications and challenges. PLOS Digital\nHealth. <\/em>2022;1(6):e0000052-e0000052.<\/li>
  22. Mohammadi M, Nikzad A.\nSustainable and reliable closed-loop supply chain network design during\npandemic outbreaks and disruptions. Operations\nManagement Research. <\/em>2023;16(2):969-991.<\/li>
  23. Chung S, Marlow S, Tobias N, et\nal. Lessons from countries implementing find, test, trace, isolation and\nsupport policies in the rapid response of the COVID-19 pandemic: a systematic\nreview. BMJ Open. <\/em>2021;11(7):e047832-e047832.<\/li>
  24. Alshrari A.S., Hudu, S.A.,\nImran M., et al. Rabbani, S.I. Innovations and development of COVID-19\nvaccines: A patent review. Journal of Infection and Public Health. 2022 15(1),\n123-131. doi: 10.1016\/j.jiph.2021.10.021.<\/li>
  25. Zhao X, Li M, Haihambo N, et\nal. Changes in Temporal Properties of Notifiable Infectious Disease Epidemics\nin China During the COVID-19 Pandemic: Population-Based Surveillance Study. JMIR Public Health and Surveillance. <\/em>2022;8(6):e35343-e35343.<\/li>
  26. Engelmann L. Coinfection,\nComorbidity, and Syndemics: On the Edges of Epidemic Historiography. Isis. <\/em>2023;114(S1):S71-S84.doi\/epdf\/10.1086\/726981<\/li>
  27. Yoo W, Choi D-H. Predictors of\nexpressing and receiving information on social networking sites during MERS-CoV\noutbreak in South Korea. Journal of Risk\nResearch. <\/em>2020;23(7-8):912-927.<\/li>
  28. Kim Y. Outbreak news production\nas a site of tension: Journalists\u2019 news-making of global infectious disease. Journalism. <\/em>2022;23(1):171-188.<\/li>
  29. Augustynowicz A, Opolski J,\nWaszkiewicz M. Resilient Health and the Healthcare System. A Few Introductory\nRemarks in Times of the COVID-19 Pandemic. International\nJournal of Environmental Research and Public Health. <\/em>2022;19(6):1-8.<\/li>
  30. Grimm P, Oliver S, Merten S,\nHan W, Wyss K. Enhancing the understanding of resilience in health systems of\nlow-and middle-income countries: a qualitative evidence synthesis. International Journal of Health Policy and\nManagement. <\/em>2022;11(7):899-911.<\/li>
  31. Mehedi N. Experiences of the\nFrontline Healthcare Professionals Amid the COVID-19 Health Hazard: A\nPhenomenological Investigation. Inquiry:\na Journal of Medical Care Organization, Provision and Financing. <\/em>2022;59:469580221111925-469580221111925.<\/li>
  32. Pala A, Chuang J, Chien A, et\nal. Depression, anxiety, and burnout among hospital workers during the COVID-19\npandemic: A cross-sectional study. Plos\none. <\/em>2022;17(12):e0276861-e0276861.<\/li>
  33. Sprung CL, Devereaux AV,\nGhazipura M, et al. Critical Care Staffing in Pandemics and Disasters: A\nConsensus Report From a Subcommittee of the Task Force for Mass Critical\nCare\u2013Systems Strategies to Sustain the Health Care Workforce. Chest. <\/em>2023;164(1):124-136.<\/li>
  34. Proserpio P, Zambrelli E, Lanza\nA, et al. Sleep disorders and mental health in hospital workers during the\nCOVID-19 pandemic: a cross-sectional multicenter study in Northern Italy. Neurological Sciences. <\/em>2022:43(4):2241-2251.<\/li>
  35. Mehta A, Awuah W, Ng J, et al.\nElective surgeries during and after the COVID-19 pandemic: Case burden and\nphysician shortage concerns. Annals of\nMedicine and Surgery. <\/em>2022;81:104395-104395.<\/li>
  36. Frio G, Russo L, de Albuquerque\nC, et al. The disruption of elective procedures due to COVID-19 in Brazil in\n2020. Scientific Reports. <\/em>2022;12(1):10942-10942.<\/li>
  37. Palmer CS. Innate metabolic\nresponses against viral infections. Nature\nMetabolism. <\/em>2022;4(10):1245-1259.<\/li>
  38. Suardi C, Cazzaniga E, Graci S,\nDongo D, Palestini P. Link between Viral Infections, Immune System,\nInflammation and Diet. International\nJournal of Environmental Research and Public Health. <\/em>2021;18(5):2455-2455.<\/li>
  39. Han AX, de Jong SP, Russell CA.\nCo-evolution of immunity and seasonal influenza viruses. Nature Reviews Microbiology. <\/em>2023:1-13.<\/li>
  40. Mirzaei R, Goodarzi P, Asadi M,\net al. Bacterial co\u2010infections with SARS\u2010CoV\u20102. IUBMB life. <\/em>2020;72(10):2097-2111.<\/li>
  41. Dunning J, Thwaites RS,\nOpenshaw PJ. Seasonal and pandemic influenza: 100 years of progress, still much\nto learn. Mucosal immunology. <\/em>2020;13(4):566-573.<\/li>
  42. Metzger DW, Sun K. Immune\ndysfunction and bacterial coinfections following influenza. The Journal of Immunology. <\/em>2013;191(5):2047-2052.<\/li>
  43. Morris D, Cleary D, Clarke S.\nSecondary Bacterial Infections Associated with Influenza Pandemics. Frontiers in Microbiology. <\/em>2017;8:1041-1041.<\/li>
  44. Page L, Staples K, Spalluto C,\nWatson A, Wilkinson T. Influence of Hypoxia on the Epithelial-Pathogen\nInteractions in the Lung: Implications for Respiratory Disease. Frontiers in Immunology. <\/em>2021;12:653969-653969.<\/li>
  45. St\u00f6lting H, Baillon L, Frise R,\net al. Distinct airway epithelial immune responses after infection with\nSARS-CoV-2 compared to H1N1. Mucosal\nimmunology. <\/em>2022;15(5):952-963.<\/li>
  46. Morrison C, Edwards C, Shaffer\nK, et al. SARS-CoV-2 infection of airway cells causes intense viral and cell\nshedding, two spreading mechanisms affected by IL-13. Proceedings of the National Academy of Sciences of the United States of\nAmerica. <\/em>2022;119(16):e2119680119-e2119680119.<\/li>
  47. Cilloniz C, Luna C, Hurtado J,\nMarcos M, Torres A. Respiratory viruses: their importance and lessons learned\nfrom COVID-19. European Respiratory\nReview. 2<\/em>022;31(166):220051-220051.<\/li>
  48. Verma G, Dhawan M, Saied A,\nKaur G, Kumar R, Emran T. Immunomodulatory approaches in managing lung\ninflammation in COVID-19: A double-edge sword. Immunity, Inflammation and Disease. <\/em>2023;11(9):e1020-e1020.<\/li>
  49. Devi P, Yadav A, Yadav S, et\nal. Role of co-infections in modulating disease severities and clinical\nphenotypes. Genomic Surveillance and\nPandemic Preparedness. <\/em>2023:151-186.<\/li>
  50. Devi P, Khan A, Chattopadhyay\nP, et al. Co-infections as Modulators of Disease Outcome: Minor Players or\nMajor Players? Frontiers in Microbiology.\n<\/em>2021;12:664386-664386.<\/li>
  51. Reaser JK, Hunt BE,\nRuiz-Aravena M, et al. Fostering landscape immunity to protect human health: A\nscience-based rationale for shifting conservation policy paradigms. Conservation Letters. <\/em>2022;15(3):e12869.<\/li>
  52. Grifoni A, Alonzi T, Alter G,\net al. Impact of aging on immunity in the context of COVID-19, HIV, and\ntuberculosis. Frontiers in Immunology. <\/em>2023;14:1146704-1146704.<\/li>
  53. Sieber P, Flury D, G\u00fcsewell S,\net al. Characteristics of patients with Coronavirus Disease 2019 (COVID-19) and\nseasonal influenza at time of hospital admission: a single center comparative\nstudy. BMC Infectious Diseases. <\/em>2021;21(1):1-9.<\/li>
  54. Jiang C, Yao X, Zhao Y, et al.\nComparative review of respiratory diseases caused by coronaviruses and\ninfluenza A viruses during epidemic season. Microbes\nand infection. <\/em>2020;22(6-7):236-244.<\/li>
  55. El-Radhi AS. Fever in common\ninfectious diseases. Clinical Manual of\nFever in Children. <\/em>2018:85-140.<\/li>
  56. Jaworski CA, Donohue B, Kluetz\nJ. Infectious disease. Clinics in sports\nmedicine. <\/em>2011;30(3):575-590.<\/li>
  57. Huff HV,\nSingh A. Asymptomatic transmission during the coronavirus disease 2019 pandemic\nand implications for public health strategies. Clinical Infectious Diseases.\n2020;71(10):2752-6.<\/li>
  58. El-Sadr WM,\nPlatt J, Bernitz M, Reyes M. Contact tracing: barriers and facilitators.\nAmerican Journal of Public Health. 2022;112(7):1025-33.<\/li>
  59. Prashanth LK,\nTaly AB, Sinha S, Arunodaya GR, Swamy HS. Wilson’s disease: diagnostic errors\nand clinical implications. Journal of Neurology, Neurosurgery, and Psychiatry.\n2004;75(6):907-9.<\/li>
  60. Klinkenberg\nD, Fraser C, Heesterbeek H. The effectiveness of contact tracing in emerging\nepidemics. PloS one. 2006;1(1):e12.<\/li>
  61. Watson SK,\nRudge JW, Coker R. Health systems\u2019\u201csurge capacity\u201d: state of the art and\npriorities for future research. The Milbank Quarterly. 2013;91(1):78-122.<\/li>
  62. Kappler S,\nWiesner L, Davis S. Pandemic Preparedness and Response. Ciottone’s Disaster\nMedicine 2024 Jan 1 (pp. 36-42). Elsevier.<\/li>
  63. Hudu SA, Alshrari\nAS. Preparedness in Containment of Coronavirus Disease-19 in the African\nContinent. Bioscience Biotechnology Research Communications. 2020;13(3):1623-9.<\/li>
  64. Baldassarre\nA, Giorgi G, Alessio F, Lulli LG, Arcangeli G, Mucci N. Stigma and discrimination\n(SAD) at the time of the SARS-CoV-2 pandemic. International journal of\nenvironmental research and public health. 2020;17(17):6341.<\/li>
  65. Adinkrah EK,\nCobb S, Bazargan M. Delayed Medical Care of Underserved Middle-Aged and Older\nAfrican Americans with Chronic Disease during COVID-19 Pandemic. Healthcare.\n2023;11(4):595-595.<\/li>
  66. Pozo-Martin\nF, Beltran Sanchez MA, M\u00fcller SA, Diaconu V, Weil K, El Bcheraoui C.\nComparative effectiveness of contact tracing interventions in the context of\nthe COVID-19 pandemic: a systematic review. European Journal of Epidemiology.\n2023;38(3):243-66.<\/li>
  67. Connolly C, Keil R, Ali SH.\nExtended urbanisation and the spatialities of infectious disease: Demographic\nchange, infrastructure and governance. Urban\nstudies. <\/em>2021;58(2):245-263.<\/li>
  68. Bakker H, Bindewald V, Dunke F,\nNickel S. Logistics for diagnostic testing: An adaptive decision-support\nframework. European Journal of\nOperational Research. 2023;311(3) 1120-1133\nhttps:\/\/doi.org\/10.1016\/j.ejor.2023.05.028<\/em>.<\/li>
  69. Gavina K, Franco L, Khan H,\nLavik J, Relich R. Molecular point-of-care devices for the diagnosis of\ninfectious diseases in resource-limited settings-A review of the current\nlandscape, technical challenges, and clinical impact. Journal of Clinical Virology. <\/em>2023;169:105613-105613.<\/li>
  70. Kucirka LM, Lauer SA,\nLaeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse\ntranscriptase polymerase chain reaction\u2013based SARS-CoV-2 tests by time since\nexposure. Annals of internal medicine. <\/em>2020;173(4):262-267.<\/li>
  71. Haldane V, De Foo C, Abdalla\nSM, et al. Health systems resilience in managing the COVID-19 pandemic: lessons\nfrom 28 countries. Nature Medicine. <\/em>2021;27(6):964-980.<\/li>
  72. Abbey E, Khalifa B, Oduwole M,\net al. The Global Health Security Index is not predictive of coronavirus\npandemic responses among Organization for Economic Cooperation and Development\ncountries. Plos one. <\/em>2020;15(10):e0239398-e0239398.<\/li>
  73. Li W, Yang Y, Ng CH, et al.\nGlobal imperative to combat stigma associated with the coronavirus disease 2019\npandemic. Psychological medicine. <\/em>2021;51(11):1957-1958.<\/li>
  74. Sattler S, Maskileyson D,\nRacine E, Davidov E, Escande A. Stigmatization in the context of the COVID-19\npandemic: a survey experiment using attribution theory and the familiarity\nhypothesis. BMC Public Health. <\/em>2023;23(1):521-521.<\/li>
  75. Stenseth N, Schlatte R, Liu X,\net al. How to avoid a local epidemic becoming a global pandemic. Proceedings of the National Academy of\nSciences of the United States of America. <\/em>2023;120(10):e2220080120-e2220080120.<\/li>
  76. Coppola DP, Milliken B.\nIncident Command (IC) Role in Coordination (Logistics and Politics).\nInternational Perspective. The Path of\nFlames<\/em>: CRC Press; 2024:69-86.<\/li>
  77. Agyarko R, Al Slail F, Garrett\nDO, et al. The imperative for global cooperation to prevent and control\npandemics. Modernizing Global Health\nSecurity to Prevent, Detect, and Respond<\/em>: Elsevier; 2024:53-69.<\/li>
  78. Bloom D, Cadarette D.\nInfectious Disease Threats in the Twenty-First Century: Strengthening the\nGlobal Response. Frontiers in Immunology.\n<\/em>2019;10:549-549.<\/li>
  79. Zhang Z, Shi L, Liu N, et al.\nCoverage and impact of influenza vaccination among children in Minhang\nDistrict, China, 2013-2020. Frontiers in\nPublic Health. <\/em>2023;11:1193839-1193839.<\/li>
  80. Lazarus JV, Mark HE,\nVillota-Rivas M, et al. The global NAFLD policy review and preparedness index:\nare countries ready to address this silent public health challenge? Journal of Hepatology. <\/em>2022;76(4):771-780.<\/li>
  81. Aruru M, Truong H-A, Clark S.\nPharmacy Emergency Preparedness and Response (PEPR): a proposed framework for\nexpanding pharmacy professionals\u2019 roles and contributions to emergency\npreparedness and response during the COVID-19 pandemic and beyond. Research in Social and Administrative\nPharmacy. <\/em>2021;17(1):1967-1977.<\/li>
  82. Maddah N, Verma A, Almashmoum\nM, Ainsworth J. Effectiveness of Public Health Digital Surveillance Systems for\nInfectious Disease Prevention and Control at Mass Gatherings: Systematic\nReview. Journal of Medical Internet\nResearch. <\/em>2023;25:e44649-e44649.<\/li>
  83. Jia P, Liu S, Yang S.\nInnovations in Public Health Surveillance for Emerging Infections. Annual Review of Public Health. <\/em>2023;44:55-74.<\/li>
  84. Berg SH, O\u2019Hara JK, Shortt MT,\net al. Health authorities\u2019 health risk communication with the public during pandemics:\na rapid scoping review. BMC Public\nHealth. <\/em>2021;21(1):1-23.<\/li>
  85. Stevens DL, Bryant AE. Endemic,\nepidemic and pandemic infections: the roles of natural and acquired herd\nimmunity. Current Opinion in Infectious\nDiseases. <\/em>2023;36(3):171-176.<\/li>
  86. Meyer D, Bishai D, Ravi S, et\nal. A checklist to improve health system resilience to infectious disease\noutbreaks and natural hazards. BMJ Global\nHealth. <\/em>2020;5(8):e002429-e002429.<\/li>
  87. Girum T, Lentiro K, Geremew M,\nMigora B, Shewamare S. Global strategies and effectiveness for COVID-19\nprevention through contact tracing, screening, quarantine, and isolation: a\nsystematic review. Tropical medicine and\nhealth. <\/em>2020;48:1-15.<\/li>
  88. Venter M, Richter K. Towards\neffective diagnostic assays for COVID-19: a review. Journal of Clinical Pathology. <\/em>2020;73(7):370-377.<\/li>
  89. Oza S, Chen F, Selser V, et al.\nCommunity-Based Outbreak Investigation And Response: Enhancing Preparedness,\nPublic Health Capacity, And Equity: Commentary examines Community-Based\nOutbreak Investigation And Response, a local public health strategy developed\nduring the COVID-19 pandemic. Health\nAffairs. <\/em>2023;42(3):349-356.<\/li>
  90. Ehrlich H, Boneva D, Elkbuli A.\nThe intersection of viral illnesses: A seasonal influenza epidemic amidst the\nCOVID-19 pandemic. Vol 60: Elsevier; 2020:41-43.<\/li>
  91. Jones N. How COVID-19 is\nchanging the cold and flu season. Nature.\n<\/em>2020;588(7838):388-390.<\/li>
  92. Batta I, Kaur T, Agrawal D.\nDistinguishing Swine Flu (H1N1) from COVID-19: Clinical, Virological, and\nImmunological Perspectives. Archives of\nMicrobiology & Immunology. <\/em>2023;7(4):271-280.<\/li>
  93. Harris G, Rak K, Kahn J, et al.\nUS Hospital Capacity Managers’ Experiences and Concerns Regarding Preparedness\nfor Seasonal Influenza and Influenza-like Illness. JAMA Network Open. <\/em>2021;4(3):e212382-e212382.<\/li>
  94. Dombr\u00e1di V, Jo\u00f3 T, Palla G,\nPollner P, Belicza \u00c9. Comparison of hesitancy between COVID-19 and seasonal\ninfluenza vaccinations within the general Hungarian population: a\ncross-sectional study. BMC Public Health.\n<\/em>2021;21(1):2317-2317.<\/li>
  95. Lan C, Chen Y, Chang Y, Chuang\nP. Impact of COVID-19 Outbreak on Influenza and Pneumococcal Vaccination\nUptake: A Multi-Center Retrospective Study. Vaccines.\n<\/em>2023;11(5):986-986.<\/li><\/ol>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    Introduction Infectious diseases pose a significant threat to global public […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[113],"tags":[],"class_list":["post-56921","post","type-post","status-publish","format-standard","hentry","category-vol17no1"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/56921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=56921"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/56921\/revisions"}],"predecessor-version":[{"id":57374,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/56921\/revisions\/57374"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=56921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=56921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=56921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}